The Combination of Salbutamol Nebulizer and Oral Procaterol to the Indonesian Children with Pneumonia

Document Type : Research Paper

Authors

1 Department of Clinical Pharmacy, Faculty of Pharmacy, Ahmad Dahlan University, Yogyakarta, Indonesia.

2 Department of Clinical Pharmacy, Faculty of Pharmacy, Ahmad Dahlan University, Yogyakarta, Indonesia

10.22034/ijps.2019.104391.1533

Abstract

This study aimed to examine the effectiveness of combining salbutamol nebulizer and oral procaterol compared to only oral procaterol on the respiratory rate, temperature (fever), spasm, cough frequency, thoracic retraction, and length of stay (LOS) among young children with pneumonia. This prospective cohort study included 48 consecutive sampling subjects with pneumonia in Indonesia. The subjects were classified based on the type of therapy they received: intervention group used the combination of salbutamol nebulizer and oral procaterol therapy (n=24 subjects) and the control group received oral procaterol only (n=24). The result showed that the combination therapy salbutamol nebulizer and oral procaterol was more effective than the administration of oral procaterol only with the rate of clinical change. Combination therapy nebulized salbutamol and oral procaterol significantly respiratory rate (p=0.006) and temperature (fever) (p=0.002) compared to the only oral procaterol. The combination had clinical change in reducing spasm, cough frequency, thoracic retraction, and length of stay (LOS) however there are was no significant effect of this combination in reducing spasm (p=0.348), cough frequency (p=0.964), thoracic retraction (p=0.666), and length of stay (LOS) (p=0.192) compared to the only oral procaterol among the Indonesian children with pneumonia.

Keywords

References

[1] World Health Organization. Revised WHO classification and treatment of childhood pneumonis at health facilities evidence summaries, WHO Press: Switzerland (2014).
[2] United Nations Children’s Fund. Levels & Trends in Child Mortality, Report 2018, United Nations Children’s Fund: New York, New York, USA (2018).
[3] World Health Organization. Ending preventable child deaths from pneumonia and Diarrhoea by 2025 the integrated global action plan for pneumonia and Diarrhoea. WHO Press: Switzerland (2013).
[4] Singh SR, Krishnamurty, Mathew BB. A review on recent diseases caused by microbes. Appl. Environ. Microbiol. (2014) 2 (4): 106-115.
[5] Misnadiarly. Pneumonia Infections in Children, Adults, and Geriatric, 1st ed., Pustaka Obor Populer: Jakarta (2008).
[6] Hockenberry, Marilyn J, David W. Wong's Essentials of Pediatric Nursing, 8th ed., Elsevier Health Sciences: St. Louis (2013).
[7] Lalani A, Schneeweiss S. Handbook of pediatric emergency medicine, Jones & Bartlett: Toronto, Canada  (2008).
[8] Kozier B, Fundamental of Nursing Consepts, Processes, and Practice, Pearson Education: Jakarta (2008).
[9] Li B, Han S, Liu F, Kang L, Xv C. Budesonide Nebulization in the Treatment of Neonatal Ventilator Associated Pneumonia. Pak. J. Med. Sci. (2017) 33 (4): 997-1001.
[10] Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, Torres A. Etiology of community-acquired pneumonia impact of age, comorbidity, and severity. Am. J. Respir. Crit .Care Med. (1999)160(2): 397-405.
[11] Herman. Factor associated with the incidence of pneumonia in children under five years in the district of Sumatera Selatan. Thesis, University of Indonesia: Depok (2002).
[12] Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, Thomson A. British Thoracic Society guidelines for the management of community acquired pneumonia in children. Thorax (2011) 66 (2): 1-23.
[13] Darcy M, Nana A, Rabe K, Zar H, Ferkol T, Oca MM, Billo N. Respiratory diseases in the world, European Respiratory Society publications office: Glossop Road, Sheffield, UK (2013).
[14] Hazir T, Nisar Y, Abbasi S, Ashraf YP, Khurshid J, Tariq P, Maqbool S. Comparison of oral amoxicillin with placebo for the treatment of World Health Organization defined nonsevere pneumonia in children aged 2-59 months: A multicenter, double-blind, randomized, placebo-controlled trial in Pakistan. Clin. Infect. Dis. (2011) 52 (3): 293–300.
[15] Yuan., George, Drost., Nicole A. Mcivor R. Andrew. Respiratory rate and breathing pattern. McMaster Univ. Med. J. (2013)10 (1): 23-25.
[16] Tamaoki J, Asthma prevention and management guideline. Arerugi (2018)67 (9): 1263-1268.
[17] Global Asthma Network. The Global Asthma Report 2018, The Global Asthma Network: Auckland, New Zealand (2018).
[18] Barnes, Peter J. Effect of beta-agonists on airway effector cells. Lung Biology in Health and Disease (1997) 106: 35-66.
[19] Miyamoto T, Takishima T, Takahashi T, Nakajima S, Yamakido M, Nakajima M. Clinical evaluation of HN-078, a patch formulation of tulobuterol, in patients with bronchial asthma on the late phase II study. J.  Clin.  Therap. Med. (1995) 11: 761-78.
 
Iranian Journal of Pharmaceutical Sciences
Volume 16, Issue 3
July 2020
Pages 59-72

Files

Share

How to cite

Statistics